Dauntless 1's Series A Round

Dauntless 1 raised a round of funding on June 10, 2015.

Dauntless 1 is developing a therapeutic agent, DP1038, for the treatment of endocrine cancers in Dauntless 1. DP1038 will follow a 505(b)(2) pathway to speed development and reduce costs. DP1038 compl…

Articles about Dauntless 1's Series A Round: